AHACW
Alpha Healthcare Acquisition Corp. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "d6c4a630-de33-4fd4-b3b1-3b6fcbc4a168",
"title": "Humacyte First Quarter 2024 Financial Results and Business Update",
"description": "-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August...",
"keywords": "Nasdaq:HUMA, Humacyte, Inc",
"snippet": "-Biologics License Application (BLA) for HAV™ Accepted by FDA-\n\n\n\n-BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2...",
"url": "https://www.globenewswire.com/news-release/2024/05/10/2879547/0/en/Humacyte-First-Quarter-2024-Financial-Results-and-Business-Update.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/e81aff26-ead8-404d-aebb-159b45c3e7b1",
"language": "en",
"published_at": "2024-05-10T11:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "AHACW",
"name": "Alpha Healthcare Acquisition Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 14.687287,
"sentiment_score": -0.2023,
"highlights": [
{
"highlight": "The decrease in other net expense for the first quarter of 2024 compared to 2023 resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with the Company’s August 2021 merger with <em>Alpha</em> <em>Healthcare</em> <em>Acquisition</em> <em>Corp</em>.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "AHACW",
"total_documents": 1,
"sentiment_avg": -0.20229999721050262
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- N/A
- us